Premium
Sorafenib use in the transplant setting
Author(s) -
Castelli Giulia,
Burra Patrizia,
Giacomin Anna,
Vitale Alessandro,
Senzolo Marco,
Cillo Umberto,
Farinati Fabio
Publication year - 2014
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1002/lt.23911
Subject(s) - sorafenib , medicine , hepatocellular carcinoma , adjuvant , liver transplantation , oncology , toxicity , milan criteria , transplantation
Liver transplantation (LT) is an established treatment for hepatocellular carcinoma (HCC), and sorafenib (SFN) is a validated treatment for patients harboring advanced tumors. It is still not clear whether the combination of the 2 treatments, with SFN used in the neoadjuvant, adjuvant, or recurrence setting, is useful and cost‐effective. This article summarizes the present evidence in favor of and against the use of SFN in the setting of LT for HCC, and it also includes the problem of toxicity, particularly when mammalian target of rapamycin inhibitors, which play a central role in regulating cellular growth and proliferation, are used as immunosuppressants. Overall, the data do not support the use of SFN in the pre‐ or post‐LT setting as adjuvant therapy, and additional studies are needed to reach sound conclusions on the topic. Liver Transpl 20:1021–1028, 2014 . © 2014 AASLD.